These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 9144906)

  • 1. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group.
    Jonas U; Höfner K; Madersbacher H; Holmdahl TH
    World J Urol; 1997; 15(2):144-51. PubMed ID: 9144906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients.
    Zinner NR; Mattiasson A; Stanton SL
    J Am Geriatr Soc; 2002 May; 50(5):799-807. PubMed ID: 12028164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.
    Homma Y; Paick JS; Lee JG; Kawabe K;
    BJU Int; 2003 Nov; 92(7):741-7. PubMed ID: 14616458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder.
    Jacquetin B; Wyndaele J
    Eur J Obstet Gynecol Reprod Biol; 2001 Sep; 98(1):97-102. PubMed ID: 11516807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.
    Van Kerrebroeck P; Kreder K; Jonas U; Zinner N; Wein A;
    Urology; 2001 Mar; 57(3):414-21. PubMed ID: 11248608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.
    Chapple CR; Rechberger T; Al-Shukri S; Meffan P; Everaert K; Huang M; Ridder A;
    BJU Int; 2004 Feb; 93(3):303-10. PubMed ID: 14764127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
    Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials.
    Nijman RJ; Borgstein NG; Ellsworth P; Djurhuus JC
    J Urol; 2005 Apr; 173(4):1334-9. PubMed ID: 15758796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.
    Chapple CR; Araño P; Bosch JL; De Ridder D; Kramer AE; Ridder AM
    BJU Int; 2004 Jan; 93(1):71-7. PubMed ID: 14678372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia.
    Van Kerrebroeck PE; Amarenco G; Thüroff JW; Madersbacher HG; Lock MT; Messelink EJ; Soler JM
    Neurourol Urodyn; 1998; 17(5):499-512. PubMed ID: 9776013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study.
    Rentzhog L; Stanton SL; Cardozo L; Nelson E; Fall M; Abrams P
    Br J Urol; 1998 Jan; 81(1):42-8. PubMed ID: 9467475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolterodine: a safe and effective treatment for older patients with overactive bladder.
    Malone-Lee JG; Walsh JB; Maugourd MF
    J Am Geriatr Soc; 2001 Jun; 49(6):700-5. PubMed ID: 11454106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
    Diokno AC; Appell RA; Sand PK; Dmochowski RR; Gburek BM; Klimberg IW; Kell SH;
    Mayo Clin Proc; 2003 Jun; 78(6):687-95. PubMed ID: 12934777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine.
    Freeman R; Hill S; Millard R; Slack M; Sutherst J;
    Obstet Gynecol; 2003 Sep; 102(3):605-11. PubMed ID: 12962951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.
    Abrams P; Freeman R; Anderström C; Mattiasson A
    Br J Urol; 1998 Jun; 81(6):801-10. PubMed ID: 9666761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder.
    Swift S; Garely A; Dimpfl T; Payne C;
    Int Urogynecol J Pelvic Floor Dysfunct; 2003 Feb; 14(1):50-4; discussion 54-5. PubMed ID: 12601517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity.
    Ethans KD; Nance PW; Bard RJ; Casey AR; Schryvers OI
    J Spinal Cord Med; 2004; 27(3):214-8. PubMed ID: 15478523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolterodine use for symptoms of overactive bladder.
    Ruscin JM; Morgenstern NE
    Ann Pharmacother; 1999 Oct; 33(10):1073-82. PubMed ID: 10534221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data.
    Larsson G; Hallén B; Nilvebrant L
    Urology; 1999 May; 53(5):990-8. PubMed ID: 10223495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolterodine: a clinical review.
    Crandall C
    J Womens Health Gend Based Med; 2001 Oct; 10(8):735-43. PubMed ID: 11703885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.